$Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study$

Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study

Background Immune checkpoint inhibitors (ICIs) in combination with antiangiogenic drugs have shown promising outcomes in the third-line and subsequent treatments of patients with microsatellite stable metastatic colorectal cancer (MSS-mCRC). Radiotherapy (RT) may enhance the antitumor effect of immu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jing Wang, Tao Zhang, Lei Zhao, Min Jin, Pindong Li, Shengli Yang, Hong Ma, Zhenyu Lin, Junli Liu, Hongli Liu, Kunyu Yang, Dandan Yu, Jianli Hu, Jun Xue, Mingxia Cheng, Chuying Huang
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/1/e009415.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter to the editor: effects of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer—a prospective observation study
by: Bi-Cheng Wang
Published: (2025-02-01)

Fruquintinib and sintilimab plus SOX as perioperative therapy for locally resectable advanced gastric/gastroesophageal junction adenocarcinoma: study protocol for a prospective, single-arm, phase II clinical trial
by: Xiangyu Meng, et al.
Published: (2025-07-01)

Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial
by: Rui Liu, et al.
Published: (2025-02-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Clinical Progress of Fruquintinib in Colorectal Cancer: An Overview
by: Yejie Xie, et al.
Published: (2025-02-01)

Safety and efficacy of systemic chemotherapy plus PD-1 inhibitor in combination with intravenous or intraperitoneal bevacizumab in gastric cancer with peritoneal metastasis
by: Yuxi Ma, et al.
Published: (2025-06-01)

Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
by: Kunyuan Wang, et al.
Published: (2025-06-01)

Raltitrexed, S-1 and fruquintinib (RSF) in the treatment of refractory metastatic colorectal cancer: study protocol for a multicenter, prospective, single-arm, phase II trial
by: Weibing Leng, et al.
Published: (2025-02-01)

The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma
by: Chenglong Zhao, et al.
Published: (2025-06-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

FRESCO–2 trial and fruquintinib: A clearer picture of the control arm
by: Sruthi Ranganathan, et al.
Published: (2025-08-01)

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
by: Jing Liu, et al.
Published: (2025-07-01)

Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial
by: Jingjing Li, et al.
Published: (2025-07-01)

Assessment of Food Effect and pH‐Dependent Drug–Drug Interactions of Fruquintinib in Healthy Subjects
by: Martha Gonzalez, et al.
Published: (2025-03-01)

Sintilimab plus lenvatinib in combination with transarterial chemoembolization and subsequent radiofrequency ablation for unresectable hepatocellular carcinoma: a single-arm, single-center study
by: Xiaochun Chen, et al.
Published: (2025-07-01)

Sintilimab plus bevacizumab followed by resection in intermediate-stage hepatocellular carcinoma: a phase Ib clinical trial with biomarker analysis
by: Jia Fan, et al.
Published: (2024-12-01)

Updated overall survival data and predictive biomarkers of autologous NK cells plus Sintilimab as second-line treatment for advanced non-small cell lung cancer
by: Lin Jia, et al.
Published: (2025-05-01)

Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
by: Genlin Lu, et al.
Published: (2025-01-01)

The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study
by: Yao Wang, et al.
Published: (2025-07-01)

Genomic microsatellite characterization and development of polymorphic microsatellites in Eospalax baileyi
by: Qiqi Hou, et al.
Published: (2025-01-01)

The efficacy and safety of regorafenib/fruquintinib combined with PD-1/PD-L1 for metastatic colorectal cancer: a meta-analysis based on single-arm studies
by: Fan Yang, et al.
Published: (2025-05-01)

Effect of prognostic nutritional index on laboratory parameters and survival in metastatic colorectal cancer patients treated with fruquintinib: a retrospective study
by: Zeng Wang, et al.
Published: (2024-11-01)

Safety and Efficacy of Radiotherapy Combined With Sintilimab in Advanced NSCLC Patients Who Progressed on First or Second Line Therapy: A Prospective, Multiple Center, and Single‐Arm Study
by: Xiaoyi Feng, et al.
Published: (2025-03-01)

Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study
by: Zhenlin Hou, et al.
Published: (2025-07-01)

Correction: The impact of sarcopenia on prognosis and fruquintinib efficacy in advanced colorectal cancer: a retrospective and mendelian randomization study
by: Frontiers Production Office
Published: (2025-08-01)

Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
by: Ellery Koelker-Wolfe, et al.
Published: (2025-02-01)

Subacute cutaneous lupus erythematosus triggered by sintilimab: a case report
by: Chenxi Zhang, et al.
Published: (2025-04-01)

Sintilimab-induced intestinal obstruction and hemorrhage of the digestive tract: a case report
by: Qian Hao, et al.
Published: (2025-07-01)

Case Report: Guselkumab treatment for sintilimab-exacerbated psoriasis in a cancer patient
by: Jianhao Ke, et al.
Published: (2025-06-01)

Fruquintinib inhibits the migration and invasion of colorectal cancer cells by modulating epithelial-mesenchymal transition via TGF-β/Smad signaling pathway
by: Qinqin Song, et al.
Published: (2025-03-01)

Cost-effectiveness analysis of sintilimab additional to chemoradiotherapy in high-risk locoregionally advanced nasopharyngeal carcinoma
by: Longjiang She, et al.
Published: (2025-07-01)

Sintilimab for the treatment of lung adenocarcinoma-induced immune-related hypophysitis: a case report
by: Ming-xing Wang, et al.
Published: (2025-01-01)

Fruquintinib as first‐line or second‐line treatment in unresectable or metastatic soft‐tissue sarcoma: A prospective, single‐arm phase II study
by: Xiaowei Zhang, et al.
Published: (2025-04-01)

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE
by: Wu-Kui Huang, et al.
Published: (2017-01-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
by: Jun Fan, et al.
Published: (2021-11-01)

Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 2 trial (TD-NeoFOUR trial)
by: Hongtao Duan, et al.
Published: (2024-10-01)

Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab
by: Shiyi Li, et al.
Published: (2025-03-01)

Case Report: Fruquintinib-induced hyperbilirubinemia: a rare cause of dialyzer filter discoloration in a patient undergoing long-term dialysis
by: Mercedes Galloway, et al.
Published: (2025-07-01)

SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved remarkable tumor regression: case report and literature review
by: Jie Dong, et al.
Published: (2025-04-01)